RLAY (Relay Therapeutics Inc) Earnings per share for the last four quarters

Public company logo of Relay Therapeutics Inc (RLAY)

Relay Therapeutics (RLAY) relies on partnerships with tech giants to accelerate the discovery of cancer treatments. On GURU.Markets, the relative EPS YoY TTM growth rate reflects profit dynamics, with the value holding around 13.90, which is critical for a non-cyclical sector resilient to crises. Meanwhile, the company is implementing AI protein modeling to create a high-tech pipeline of innovative small molecules.

RLAY relaytx.com Earnings per share for the last twelve months (02/11/2024 - 11/15/2026)

Relay Therapeutics Inc - analytical breakdowns and key metrics (RLAY)

- current price and projected stock value:
Price Performance Chart Relay Pharma|RLAY - Consensus Target
- business market valuation indicators:
Market Value Relay Pharma|RLAY - Enterprise Value
- business book valuation details:
Book Value per Share Relay Therapeutics|RLAY - Company Book Value|Market Value to Book Value relaytx.com|RLAY - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio Relay Therapeutics|RLAY - Long-Term Debt to Capital|Current Liabilities to Capital Relay Therapeutics, Inc.|RLAY - Company Total Debt|Debt to Book Capital Relay Pharma|RLAY - Company Long-Term Debts|Short-Term Debt Relay Therapeutics|Immediate Liquidity Ratio relaytx.com
- earnings and multiples data:
RLAY - Net Income|Expected Net Income Relay Therapeutics|RLAY - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Relay Pharma|RLAY - PEG Multiple|Business Value to Operating Income Before Depreciation Relay Pharma|RLAY - Operating profit EBITDA|Net earnings per one share for the last twelve months Relay Therapeutics|RLAY - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months relaytx.com|RLAY - Earnings growth in current year|Earnings growth forecast for next year Relay Therapeutics
- revenue and sales details:
RLAY - Company Revenue|Company Expected Revenue Relay Pharma|RLAY - Market Cap to Revenue|Market Cap to Future Revenue Ratio Relay Corp|RLAY - Sales Growth YoY (Last Twelve Months)
Fundamental valuation:Relay Therapeutics, Inc. (RLAY)
Signature product of Relay Therapeutics, Inc.

Profit dynamics are critical for Relay Therapeutics (RLAY), as its Inertia platform creates long-term patent monopolies in oncotherapy. The relative YoY EPS growth over the last 12 months filters out quarterly noise, measuring the real change in net income per share via a rolling annual interval. Analyzing this metric reveals the hidden pace of intellectual property capitalization, confirming the asset's fundamental resilience.

Competitor analysis for Relay Therapeutics

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX